Envista (NYSE:NVST) Price Target Cut to $17.50 by Analysts at The Goldman Sachs Group

Envista (NYSE:NVST) had its price objective decreased by The Goldman Sachs Group from $20.00 to $17.50 in a research report sent to investors on Friday, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

NVST has been the subject of several other research reports. Leerink Partnrs reaffirmed an underperform rating on shares of Envista in a report on Monday, February 26th. Morgan Stanley downgraded Envista from an overweight rating to an equal weight rating and decreased their target price for the company from $33.00 to $21.00 in a research report on Friday, April 26th. SVB Leerink began coverage on Envista in a report on Monday, February 26th. They set an underperform rating and a $19.00 price target for the company. Jefferies Financial Group lowered Envista from a buy rating to a hold rating and decreased their price objective for the company from $30.00 to $23.00 in a report on Friday, February 9th. Finally, TheStreet downgraded Envista from a c rating to a d+ rating in a report on Wednesday, February 7th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Hold and a consensus price target of $25.86.

Envista Price Performance

NVST opened at $19.07 on Friday. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.34. Envista has a 12-month low of $18.09 and a 12-month high of $36.14. The business has a 50 day moving average of $20.66 and a 200-day moving average of $22.50.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The business had revenue of $623.60 million during the quarter, compared to the consensus estimate of $634.85 million. During the same quarter last year, the company posted $0.38 EPS. The firm’s revenue was down .6% on a year-over-year basis. As a group, research analysts predict that Envista will post 1.26 earnings per share for the current year.

Institutional Trading of Envista

Institutional investors and hedge funds have recently made changes to their positions in the company. Headinvest LLC bought a new position in Envista in the third quarter valued at approximately $28,000. Fifth Third Bancorp boosted its holdings in shares of Envista by 98.1% in the 4th quarter. Fifth Third Bancorp now owns 1,254 shares of the company’s stock valued at $30,000 after purchasing an additional 621 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Envista in the 3rd quarter valued at $47,000. Signaturefd LLC raised its holdings in shares of Envista by 1,297.9% during the 4th quarter. Signaturefd LLC now owns 2,614 shares of the company’s stock worth $63,000 after buying an additional 2,427 shares in the last quarter. Finally, Covestor Ltd lifted its position in shares of Envista by 33.9% during the 3rd quarter. Covestor Ltd now owns 2,462 shares of the company’s stock worth $69,000 after buying an additional 624 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.